194 related articles for article (PubMed ID: 31747298)
1. Limited Assessment of Respiratory Muscle Response to Nusinersen Treatment in Infants with Spinal Muscular Atrophy.
Chacko A; Sly PD; Gauld L
Am J Respir Crit Care Med; 2020 Mar; 201(5):624. PubMed ID: 31747298
[No Abstract] [Full Text] [Related]
2. Reply to Chacko
LoMauro A; Mastella C; Alberti K; Masson R; Aliverti A; Baranello G
Am J Respir Crit Care Med; 2020 Mar; 201(5):624-626. PubMed ID: 31747301
[No Abstract] [Full Text] [Related]
3. Nusinersen improved respiratory function in spinal muscular atrophy type 2.
Tanaka R; Fukushima F; Motoyama K; Kobayashi C; Izumi I
Pediatr Int; 2021 Aug; 63(8):973-974. PubMed ID: 34245199
[No Abstract] [Full Text] [Related]
4. Effect of Nusinersen on Respiratory Muscle Function in Different Subtypes of Type 1 Spinal Muscular Atrophy.
LoMauro A; Mastella C; Alberti K; Masson R; Aliverti A; Baranello G
Am J Respir Crit Care Med; 2019 Dec; 200(12):1547-1550. PubMed ID: 31433957
[No Abstract] [Full Text] [Related]
5. Respiratory assessment in a spinal muscular atrophy infant treated with nusinersen.
Ogawa K; Okanari K; Kobayashi O; Nakashima M; Ihara K
Pediatr Int; 2019 Oct; 61(10):1051-1053. PubMed ID: 31612561
[No Abstract] [Full Text] [Related]
6. Treating adults with spinal muscular atrophy with nusinersen.
Farrar MA; Kiernan MC
J Neurol Neurosurg Psychiatry; 2020 Nov; 91(11):1139. PubMed ID: 32917825
[No Abstract] [Full Text] [Related]
7. Effect of nusinersen on respiratory function in paediatric spinal muscular atrophy types 1-3.
Chacko A; Sly PD; Ware RS; Begum N; Deegan S; Thomas N; Gauld LM
Thorax; 2022 Jan; 77(1):40-46. PubMed ID: 33963091
[TBL] [Abstract][Full Text] [Related]
8. A 5-center experience with intrathecal administration of nusinersen in SMA1 in Italy letter to the editor of european journal of pediatric neurology regarding the manuscript "single-center experience with intrathecal administration of nusinersen in children with spinal muscular atrophy type 1" written by pechmann and colleagues".
Sansone VA; Pane M; Messina S; Bruno C; D'Amico A; Albamonte E; Catteruccia M; Sframeli M; Pedemonte M; Vita G; Bertini E; Mercuri E;
Eur J Paediatr Neurol; 2018 Jul; 22(4):729-731. PubMed ID: 29673809
[No Abstract] [Full Text] [Related]
9. Assessment of respiratory muscles and motor function in children with SMA treated by nusinersen.
Gómez-García de la Banda M; Amaddeo A; Khirani S; Pruvost S; Barnerias C; Dabaj I; Bénézit A; Durigneux J; Carlier RY; Desguerre I; Quijano-Roy S; Fauroux B
Pediatr Pulmonol; 2021 Jan; 56(1):299-306. PubMed ID: 33118682
[TBL] [Abstract][Full Text] [Related]
10. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
[TBL] [Abstract][Full Text] [Related]
11. Long-term benefits of nusinersen in a child affected by cystic fibrosis and spinal muscular atrophy type 1.
Bruno G; Donnarumma B; Inverardi A; Buonpensiero P; Sepe A; Tosco A; Raia V; Varone A
Pediatr Pulmonol; 2021 Jun; 56(6):1806-1808. PubMed ID: 33684256
[No Abstract] [Full Text] [Related]
12. Nusinersen treatment in a type 3 spinal muscular atrophy patient during early pregnancy.
Schön M; Domingues S; de Carvalho M; Oliveira Santos M
Neurol Sci; 2023 May; 44(5):1803-1804. PubMed ID: 36645532
[No Abstract] [Full Text] [Related]
13. Respiratory outcome of spinal muscular atrophy type 1 patients treated with nusinersen.
Ergenekon AP; Yilmaz Yegit C; Cenk M; Gokdemir Y; Erdem Eralp E; Ozturk G; Unver O; Kenis Coskun O; Karadag Saygi E; Turkdogan D; Karadag B
Pediatr Int; 2022 Jan; 64(1):e15175. PubMed ID: 35522792
[TBL] [Abstract][Full Text] [Related]
14. Resolution of skin necrosis after nusinersen treatment in an infant with spinal muscular atrophy.
Salmin F; Albamonte E; Morettini V; Gagliano N; Mercuri E; Sansone VA
Muscle Nerve; 2019 Jun; 59(6):E42-E44. PubMed ID: 30811610
[No Abstract] [Full Text] [Related]
15. [Spinal muscular atrophy treated with nusinersen].
Boesen MS; Albrechtsen S; Born AP
Ugeskr Laeger; 2019 Jan; 181(2):. PubMed ID: 30618374
[TBL] [Abstract][Full Text] [Related]
16. Nonrespiratory complications of nusinersen-treated spinal muscular atrophy type 1 patients.
Lavie M; Rochman M; Sagi L; Yerushalmy Feler A; Ovadia D; Cahal M; Be'er M; Sadot E; Fattal-Valevski A; Amirav I
Pediatr Pulmonol; 2022 Mar; 57(3):686-694. PubMed ID: 34921596
[TBL] [Abstract][Full Text] [Related]
17. Spinal muscular atrophy with respiratory distress type 1 (SMARD1).
Kaindl AM; Guenther UP; Rudnik-Schöneborn S; Varon R; Zerres K; Schuelke M; Hübner C; von Au K
J Child Neurol; 2008 Feb; 23(2):199-204. PubMed ID: 18263757
[TBL] [Abstract][Full Text] [Related]
18. Nusinersen treatment response markers.
Fyfe I
Nat Rev Neurol; 2022 Jul; 18(7):381. PubMed ID: 35676372
[No Abstract] [Full Text] [Related]
19. Changing respiratory expectations with the new disease trajectory of nusinersen treated spinal muscular atrophy [SMA] type 1.
Fitzgerald DA; Doumit M; Abel F
Paediatr Respir Rev; 2018 Sep; 28():11-17. PubMed ID: 30414815
[TBL] [Abstract][Full Text] [Related]
20. A retrospective cohort study of children with spinal muscular atrophy type 2 receiving anesthesia for intrathecal administration of nusinersen.
Bielsky AR; Fuhr PG; Parsons JA; Yaster M
Paediatr Anaesth; 2018 Dec; 28(12):1105-1108. PubMed ID: 30284761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
